Jeff Holford is an investment analyst covering health care companies in the U.S. Equity Division. He is an Investment Advisory Committee member of the Health Sciences, Institutional International Core Equity, and Overseas Stock Funds. Jeff is a vice president of T. Rowe Price Associates, Inc. 

Jeff’s investment experience began in 2001, and he has been with T. Rowe Price since 2018, beginning in the U.S. Equity Division. Prior to this, Jeff was employed by Jefferies Financial Group as managing director with global coverage of the large-cap pharmaceutical industry . Jeff also was employed by Credit Suisse as the co-head of the European Pharmaceutical Equity Research team. 

Jeff earned a B.Sc., first-class honors, in biochemistry from the University of Surrey, School of Biological Sciences. He also earned a Ph.D. in biochemistry, with a focus on preclinical cancer drug development, molecular biology, and molecular pharmacology, from the University of London. He also has earned the Association of Chartered Certified Accountants qualification.